Abstract
Background HIV remains a major burden to the health care system and neuropathic pain is the most common neurological complication of HIV-infection. Since current treatment strategies often lack satisfying pain relief, cannabinoids are discussed as a new option. We investigated Cannabidivarin as treatment for HIV-associated neuropathic pain.
Methods We conducted a randomized, double-blind, placebo-controlled cross-over study. Patients underwent two successive treatment phases (4 weeks each) and were treated with Cannabidivarin (400mg/d) or placebo in a randomized order. A 3-week wash-out phase was designed to eliminate potential carry-overeffects and patients were followed up for 3 weeks after the end of the second treatment phase. The primary endpoint was pain intensity on an 11-point numeric rating scale and was recorded in a diary. Secondary endpoints were additional pain medication, pain characteristics and quality of life.
Results We included 32 (31 male) patients. The mean pain intensity under Cannabidivarin was by 0.62 points higher compared to placebo (p=0.16; 95% CI -0.27 to 1.51). Cannabidivarin did not influence the amount of additional pain medication, pain characteristics or quality of life. No suspected unexpected adverse reactions occurred during the trial.
Discussion Cannabidivarin was safe but failed to reduce neuropathic pain intensity in HIV-patients. This may be explained by a lack of cannabinoid receptor activation, as indicated by preclinical experiments. Further studies on larger sample sizes are needed.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
EudraCT 2014-005344-17
Funding Statement
The study was funded by the European Commission (EU FP7-HEALTH-2013-INNOVATION-1; No. 602891-2).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data are available at the Koordinationszentrum für Klinische Studien, Charité Universitätsmedizin Berlin, Germany
